Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1770034 Target Snapshot

Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma · SINGLE PROTEIN · Homo sapiens

655Compounds
177Assays
10Approved Drugs
494.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q8TBX8. Use UniProt Q8TBX8 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q8TBX8 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma as ChEMBL target CHEMBL1770034, mapped to UniProt Q8TBX8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1770034
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q8TBX8
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma is the right protein anchor across sources, using UniProt Q8TBX8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPhosphatidylinositol 5-phosphate 4-kinase type-2 gamma
UniProt AccessionQ8TBX8
Component TypeProtein
Sequence Length421 aa

Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, mapped to UniProt Q8TBX8. Sequence length is 421 aa.

Mapped IDQ8TBX8
Review namePhosphatidylinositol 5-phosphate 4-kinase type-2 gamma
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

10
Approved
3
Phase III
12
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC5068.0
KD426.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4454033 10.64 Kd 0.023 Preclinical
CHEMBL4436648 8.8 Kd 1.6 Preclinical
CHEMBL3688339 8.52 Kd 3.0 Preclinical
CHEMBL4455633 8.47 Kd 3.4 Preclinical
CHEMBL4446338 8.32 Kd 4.8 Preclinical
CHEMBL5653589 8.28 Kd 5.258 Preclinical
CHEMBL5440409 8.15 Kd 7.1 Preclinical
CHEMBL5394000 8.1 IC50 7.943 Preclinical
CHEMBL5420914 8.1 IC50 7.943 Preclinical
CHEMBL5399468 7.9 IC50 12.59 Preclinical
Distribution

pChEMBL Value Distribution

35
5.0
44
5.5
30
6.0
22
6.5
27
7.0
15
7.5
7
8.0
2
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PAZOPANIB
CHEMBL477772
Approved 2009
ERLOTINIB
CHEMBL553
Approved 2004
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

177
Total Assays
203
Tested Compounds
1
Assay Types
Binding — 177 assays, 203 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 74 119 5.9
cell-based format 46 15 6.5
subcellular format 32 25 5.9
assay format 25 44 6.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine